1. Which trials are the company currently conducting for ciab and when did they start? When are results expected?
2. At the ASCO presentation the CEO said the company was about to release news on ascites and the siting of ciab for diabetes? When might we know about this?
2. Is there an important reason you are not releasing information about the progress of cell banks for the pancreatic cancer trials? Can you give us an update?
3. Could you please let us know the reason you have not made information about current trials and the progress of the cell banks available to shareholders?
4. An amount of over 600,000usd was paid to Austrianova to provide the materials for the pancreatic cancer clinical trial. Pharmacyte has now said the creation of these materials is not something Austrianova does so why was the amount paid in the first place and when will it be refunded?
5. Viacyte is a private company working on a diabetes treatment and it has received tens of millions in funding from foundations for its clinical and pre clinical work. Why has pharmacyte not been successful in attracting foundation funds even though the CEO has said he has been in discussion for such funding?
6. Are the company's expectations to enrol your first patient in the pancreatic cancer trial still on track?
7. Shareholders emails have recently been returned from investor relations. How are we to contact the company?